Results 61 to 70 of about 1,470 (198)
BMC NeurologyBackground Anti-NMDA receptor encephalitis is an autoimmune, antibody-mediated inflammatory disease of the brain characterized by the presence of IgG antibodies targeting the excitatory N-methyl-D-aspartate receptor (NMDAR).
Huasheng Huang +4 more
doaj +1 more source
Efgartigimod for generalized myasthenia gravis: A multicenter real‐world cohort study in China
Annals of Clinical and Translational NeurologyObjective Efgartigimod, a neonatal Fc receptor antagonist, facilitates antibody degradation including pathogenic IgGs. The ADAPT study demonstrated the tolerability and efficacy of efgartigimod in the treatment of generalized myasthenia gravis (gMG ...
Sushan Luo +22 more
doaj +1 more source
Short-term treatment of CIDP with efgartigimod: a case series in China
Frontiers in ImmunologyObjectiveChronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a type of autoimmune neuropathy with treatment challenges due to the limitations of standard of care therapies.
Chong Sun +30 more
doaj +1 more source
Refocusing generalized myasthenia gravis : Patient burden, disease profiles, and the role of evolving therapy [PDF]
Generalized myasthenia gravis (gMG) continues to present significant challenges for clinical management due to an unpredictable disease course, frequent disease fluctuations, and varying response to therapy.
Cortés-Vicente, Elena +5 more
core +1 more source
European Journal of Neurology, Volume 33, Issue 5, May 2026.In the Vivacity‐MG3 study, clinical response to nipocalimab was assessed using the MG‐ADL and QMG measures. Nipocalimab treatment improves gMG symptoms earlier than placebo and provides sustained disease control over the 24‐week double‐blind period.
Tuan Vu +12 more
wiley +1 more source
New insights in the immune treatment of Guillain–Barré syndrome [PDF]
Purpose of review Guillain–Barré syndrome (GBS) is a severe but treatable form of immune-mediated neuropathy. The purpose of this review is to provide an update on current immune treatments for GBS, highlight challenges in clinical practice and research,
Jacobs, Bart C., Wiegers, Eveline J.A.
core +1 more source
HLA Class I Haplotype in Glutamic Acid Decarboxylase Antibody‐Associated Neurological Disease
European Journal of Neurology, Volume 33, Issue 5, May 2026.We included 62 Chinese patients with GADAND and 990 HCs. A*11:01 ~ B*40:01 ~ C*07:02 was identified as a susceptibility haplotype; HLA haplotypes were further associated with autoimmune comorbidities, with T1DM‐risk haplotypes showing a trend toward enrichment in GADAND and A*11:01 ~ B*40:01 ~ C*07:02 significantly enriched in patients with comorbid ...
Lin Bai +11 more
wiley +1 more source
Frontiers in ImmunologyObjectiveTo analyze and compare the efficacy of ripertamab, rituximab, and efgartigimod in patients with chronic inflammatory demyelinating polyneuropathy (CIDP), focusing on treatment response rates, relapse rates, drug safety, long-term clinical ...
Yutong Wu +11 more
doaj +1 more source
Drugs in R&DEfgartigimod, a human immunoglobulin G (IgG)1-derived Fc fragment targeting the neonatal Fc receptor, has been developed into intravenous (IV) and subcutaneous (SC) formulations for treating generalized myasthenia gravis (gMG) and other autoimmune diseases. Data in the Chinese population were not available to date, and while both formulations have been
Shan Jing +11 more
openaire +3 more sources
Annals of Clinical and Translational Neurology, Volume 13, Issue 4, Page 714-723, April 2026.ABSTRACT Background Myasthenia gravis (MG) is a rare disorder characterized by fluctuating muscle weakness with potential life‐threatening crises. Timely interventions may be delayed by limited access to care and fragmented documentation. Our objective was to develop predictive algorithms for MG deterioration using multimodal telemedicine data ...
Maike Stein +7 more
wiley +1 more source